Taranjit S Gujral
Overview
Explore the profile of Taranjit S Gujral including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1059
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paatela E, St Amant F, Hamm D, Bennett S, Gujral T, van der Maarel S, et al.
bioRxiv
. 2025 Mar;
PMID: 40027792
The DUX4 transcription factor is briefly expressed in the early embryo and is epigenetically repressed in somatic tissues. Loss of epigenetic repression can result in the aberrant expression of DUX4...
2.
Farghli A, Chan M, Sherman M, Dickerson L, Shui B, Nukaya M, et al.
bioRxiv
. 2024 Dec;
PMID: 39713360
Fibrolamellar carcinoma (FLC) is a rare malignancy disproportionately affecting adolescents and young adults with no standard of care. FLC is characterized by thick stroma, which has long suggested an important...
3.
Ho C, Zhu S, Gooley T, Gujral T, Lynch R, Poh C, et al.
EJHaem
. 2024 Dec;
5(6):1173-1181.
PMID: 39691260
Background: The tumor microenvironment (TME), including infiltrating T-cells, is thought to play a major role in the pathogenesis and prognosis of follicular lymphoma (FL) and may contribute to its widely...
4.
Nguyen T, Horowitz L, Nguyen B, Lockhart E, Zhu S, Gujral T, et al.
bioRxiv
. 2024 Oct;
PMID: 39386436
The microvasculature within the tumor microenvironment (TME) plays an essential role in cancer signaling beyond nutrient delivery. However, it has been challenging to control the generation and/or maintenance of microvasculature...
5.
Gritti I, Wan J, Weeresekara V, Vaz J, Tarantino G, Bryde T, et al.
Cancer Discov
. 2024 Sep;
15(2):382-400.
PMID: 39326063
This work combines functional studies in model systems and examination of human tumor specimens to define a central oncogenic pathway driven by DNAJB1-PRKACA fusions in FLC. DNAJB1-PRKACA-mediated inactivation of the...
6.
Nguyen T, Horowitz L, Krilov T, Lockhart E, Kenerson H, Gujral T, et al.
Sci Adv
. 2024 Sep;
10(36):eadn5875.
PMID: 39241078
Functional assays on intact tumor biopsies can complement genomics-based approaches for precision oncology, drug testing, and organs-on-chips cancer disease models by capturing key therapeutic response determinants, such as tissue architecture,...
7.
Long Jr D, Chan M, Han M, Kamdar Z, Ma R, Tsai P, et al.
Cell Rep Med
. 2024 Aug;
5(9):101699.
PMID: 39208801
Fibrolamellar carcinoma (FLC) is a rare, lethal, early-onset liver cancer with a critical need for new therapeutics. The primary driver in FLC is the fusion oncoprotein, DNAJ-PKAc, which remains challenging...
8.
Lockhart E, Horowitz L, Rodriguez A, Zhu S, Nguyen T, Mehrabi M, et al.
Lab Chip
. 2024 Apr;
24(10):2683-2699.
PMID: 38651213
Cancer drug testing in animals is an extremely poor predictor of the drug's safety and efficacy observed in humans. Hence there is a pressing need for functional testing platforms that...
9.
Stepanov I, Gottshall N, Ahmadianyazdi A, Sinha D, Lockhart E, Nguyen T, et al.
bioRxiv
. 2024 Apr;
PMID: 38586030
Teaser: A low-cost robot for handling microtissues and catalyzing their use in cancer drug evaluation and personalized oncology.
10.
Horowitz L, Rodriguez-Mias R, Chang M, Zhu S, Gottshall N, Stepanov I, et al.
bioRxiv
. 2024 Apr;
PMID: 38585935
To bridge the gap between bench and bedside, there is a need for more faithful models of human cancers that can recapitulate key features of the human tumor microenvironment (TME)...